According to Straits Research, the global PD-1 and PDL-1 inhibitor market size was valued at USD 30.52 billion in 2022. It is estimated to reach USD 106.49 billion by 2031, growing at a CAGR of 14.87% during the forecast period (2023–2031).
The PD-1 and PD-L1 Inhibitor Market refers to the global industry focused on the development, production, and distribution of immune checkpoint inhibitors that target Programmed Death-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) pathways. These inhibitors are a class of immunotherapy drugs designed to enhance the body’s immune response against cancer by blocking the interaction between PD-1 receptors on T-cells and PD-L1 proteins on tumor cells.
- December 2022- Hoffman La Roche Ltd. announced that Lunsumio® (mosunetuzumab-axgb) had been approved by the U.S. Food and Drug Administration (FDA) for adult patients with relapsed/refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
- December 2022- Hoffman La Roche Ltd announced that it entered into a U.S.-focused collaboration with Pfizer to raise awareness and educate about the significance of timely COVID-19 testing, available treatment options, symptoms, and high-risk variables that can increase the likelihood of developing severe illness.
Download Free Request Sample Report @ https://straitsresearch.com/report/pd-1-and-pdl-1-inhibitor-market/request-sample
Market Growth Drivers
Increasing prevalence of cancer and autoimmune diseases.
Rising adoption of immunotherapy as a preferred treatment option.
Growing investments in pharmaceutical research and development.
Favorable government initiatives and regulatory approvals supporting market expansion.
Key Developments in the PD-1 and PDL-1 Inhibitor Market
Ongoing clinical trials and new product launches by leading pharmaceutical companies.
Collaborations and strategic partnerships among key players to enhance product development.
Advancements in biotechnology and precision medicine fueling market growth.
Segmentation Analysis of the PD-1 and PDL-1 Inhibitor Market
By Type
PD-1 Inhibitors
PDL-1 Inhibitors
By Application
Non-Small Cell Lung Cancer (NSCLC)
Melanoma
Renal Cell Carcinoma
Hodgkin Lymphoma
Others
By End-User
Hospitals
Specialty Clinics
Research Institutes
Geographic Analysis
North America: Dominating due to high adoption rates and research investments.
Europe: Growing market share with increased regulatory approvals.
Asia-Pacific: Fastest-growing region driven by rising healthcare expenditure.
Latin America & Middle East & Africa: Emerging markets with untapped opportunities.
Market Data Insights
Detailed analysis of market trends and future projections.
In-depth assessment of key market players and their strategies.
Impact of regulatory changes on market dynamics.
Buy Now@ https://straitsresearch.com/buy-now/pd-1-and-pdl-1-inhibitor-market
About Us:
Straits Research is a top provider of business intelligence, specializing in research, analytics, and advisory services, with a focus on delivering in-depth insights through comprehensive reports.
Contact Us:
Email: sales@straitsresearch.com
Address: 825 3rd Avenue, New York, NY, USA, 10022
Phone: +1 646 905 0080 (US), +91 8087085354 (India), +44 203 695 0070 (UK)
